Compare GERN & WGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GERN | WGO |
|---|---|---|
| Founded | 1990 | 1958 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Homebuilding |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 901.5M |
| IPO Year | 1996 | 1994 |
| Metric | GERN | WGO |
|---|---|---|
| Price | $1.36 | $28.30 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 10 |
| Target Price | $2.17 | ★ $42.78 |
| AVG Volume (30 Days) | ★ 9.0M | 438.2K |
| Earning Date | 05-06-2026 | 03-25-2026 |
| Dividend Yield | N/A | ★ 4.40% |
| EPS Growth | 51.85 | ★ 106.82 |
| EPS | N/A | ★ 0.87 |
| Revenue | $1,065,000.00 | ★ $1,985,674,000.00 |
| Revenue This Year | $26.91 | $5.10 |
| Revenue Next Year | $43.75 | $4.69 |
| P/E Ratio | ★ N/A | $33.07 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.04 | $26.80 |
| 52 Week High | $2.01 | $50.16 |
| Indicator | GERN | WGO |
|---|---|---|
| Relative Strength Index (RSI) | 40.83 | 36.69 |
| Support Level | $1.24 | $27.24 |
| Resistance Level | $1.46 | $32.46 |
| Average True Range (ATR) | 0.08 | 1.00 |
| MACD | -0.02 | -0.32 |
| Stochastic Oscillator | 3.85 | 0.84 |
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
Winnebago Industries manufactures Class A, B, and C motor homes along with towables, customized specialty vehicles, boats, and parts. Headquartered in Eden Prairie, Minnesota, Winnebago has been producing recreational vehicles since 1958. Revenue was $2.8 billion in fiscal 2025. Winnebago expanded into towables in 2010 with the acquisition of SunnyBrook and acquired Grand Design in 2016. Towables made up 84% of the firm's RV unit volume, up from 31% in fiscal 2016. The company's total fiscal 2025 RV unit volume was 36,911. Winnebago expanded into boating in 2018 with the purchase of Chris-Craft, bought premium motor home maker Newmar in 2019, and acquired Barletta pontoon boats in 2021. It also is developing electric and autonomous technology.